A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses
Latest Information Update: 09 Jun 2025
At a glance
- Drugs RE-104 (Primary)
- Indications Adjustment disorders
- Focus Therapeutic Use
- Sponsors Reunion Neuroscience
Most Recent Events
- 09 Jun 2025 New trial record